Activating KRAS mutations are among the earliest oncogenic genomic alterations found in pancreatic intraepithelial neoplasia (PanIN) precursor lesions and seem to be a prerequisite for the development of a fully invasive metastatic pancreatic cancer phenotype [13,14,15]. Here, KRAS is linked to pancreatic neoplasm.